Opthea Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Opthea Limited (OPT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Opthea Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 235,261M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-7.0%) for its tracked peer group.
- Growth: Opthea Limited generated -80.0% revenue growth year over year in Q4 2025, vs 7.0% for its tracked competitors combined.
- Profitability: Its -651,164.0% net margin compares with 20.0% for the peer group.
- Peer revenue share: Opthea Limited accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.00M compares with $1.20M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OPT Sales vs. its Competitors, Q4 2025
Opthea Limited reported revenue contraction of 79.95 % year on year in Q4 2025, below its competitors' combined revenue growth of 7.03 %.
With a net margin of -651,164.00 %, Opthea Limited reported lower profitability than its competitors (20.04 %).
Opthea Limited generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Opthea Limited vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Opthea Limited reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Opthea Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Opthea Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Opthea Limited's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs -80.0% for Opthea Limited. Opthea Limited's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Opthea Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Opthea Limited | - | No | No | Yes |
| Competitors combined (57) | ||||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OPT Stock Performance relative to its Competitors
OPT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 2 | Immunitybio inc | 282.9% | Outperformed |
| 3 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
| 4 | Kymera Therapeutics Inc | 282.9% | Outperformed |
| 5 | Halozyme Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Opthea Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Opthea Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Opthea Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Opthea Limited | 4,176.22 | 0.03 |
| Abbvie Inc | 504,380.80 | 64,386.00 |
| Novartis Ag | 300,933.15 | 56,674.00 |
| Amgen Inc | 238,456.96 | 38,095.00 |
| Gilead Sciences Inc | 190,887.51 | 30,457.00 |
| Regeneron Pharmaceuticals Inc | 85,401.02 | 15,534.70 |
| SUBTOTAL | 1,521,370.85 | 235,269.88 |
Sign in to see all competitors of Opthea Limited.
Sources: Opthea Limited's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Opthea Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Opthea Limited's Competitors Named by the Company
Competitive relationships identified from Opthea Limited reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Adverum Biotechnologies Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Opthea Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from Opthea Limited reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Opthea Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Recursion Pharmaceuticals Inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Opthea Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Opthea Limited | 4,176 | 373 | -2,429,716 |
| Abbvie Inc | 504,381 | 1,129,579 | 110,807 |
| Novartis Ag | 300,933 | 752,973 | 185,566 |
| Amgen Inc | 238,457 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 190,888 | 1,791,588 | -190,588 |
| Regeneron Pharmaceuticals Inc | 85,401 | 1,008,092 | 280,902 |
| PEERS TOTAL | 1,517,195 | 1,197,857 | 157,717 |
Opthea Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Immunitybio inc | United States 98.99 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Opthea Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Opthea Limited's industry classification, broader than the peer set above. Market cap in millions of $.Opthea Limited ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,302, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 238,215 | 25.65 % |
| 2 | Gilead Sciences Inc | 192,851 | 20.77 % |
| 3 | Moderna Inc | 96,423 | 10.38 % |
| 4 | Argenx Se | 58,328 | 6.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Opthea Limited | - | 0.00 % |
Market cap and industry share for the rest of Opthea Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-09-23.
Opthea Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 39.10 % (avg) | -39.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.50 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 52.00 % | 9.14 % (avg) | +42.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Opthea Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,302 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 52.00 % vs industry average 9.14 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Opthea Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Opthea Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Opthea Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 71.2 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (43.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-7.0% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Opthea Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Opthea Limited | 0.19 | 0.22 | - |
| Abbvie Inc | 0.16 | 0.75 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Opthea Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Opthea Limited | Q2 2025 | -80.0 % | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | +13.2 % | -25.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Opthea Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Opthea Limited | Q2 2025 | - | -60.6 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Opthea Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Opthea Limited | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Opthea Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Opthea Limited | - | 167,048.73 |
| Abbvie Inc | 80.45 | 7.83 |
| Novartis Ag | 21.52 | 5.31 |
| Amgen Inc | 27.23 | 6.26 |
| Gilead Sciences Inc | - | 6.27 |
| Regeneron Pharmaceuticals Inc | 19.95 | 5.50 |
| PEERS AVERAGE | 49.37 | 6.47 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.